Zobrazeno 21 - 30
of 93
pro vyhledávání: '"Jian Gu"'
Publikováno v:
Molecular and cellular biochemistry. 476(4)
Zinc finger E-box binding homeobox 1 (ZEB1) is an important transcription factor in epithelial mesenchymal transition (EMT) which participates in the numerous life processes, such as embryonic development, fibrosis and tumor progression. ZEB1 has mul
Autor:
Hongyun Zheng, Yan Li, Chunhua Song, Jian Gu, Shriya Kane, Bei Liu, Bi Hua Tan, Yongqing Tong, Mary McGrath, Anyu Bao, Zegang Wu
Publikováno v:
BMC Medical Genetics
BMC Medical Genetics, Vol 21, Iss 1, Pp 1-11 (2020)
BMC Medical Genetics, Vol 21, Iss 1, Pp 1-11 (2020)
Background Glucose-6-phosphate dehydrogenase deficiency (D-G6PD) is an X-linked recessive disorder resulted from deleterious variants in the housekeeping gene Glucose-6-phosphate 1-dehydrogenase (G6PD), causing impaired response to oxidizing agents.
Autor:
Mutsumi Okazaki, Itsuro Saito, Jian Gu, Takao Someya, Masaki Sekino, Yingyi Xiao, Yoko Tomioka, Koichi Kida
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
Scientific Reports
Scientific Reports
Early detection of compromised circulation is essential for postoperative monitoring of free flap. Hourly clinical check-ups such as inspection and palpation still result in a delay in detection. Conversely, optical reflection and temperature measure
Publikováno v:
Molecular biology reports. 48(1)
Calcium-sensing receptor (CaSR) is widely involved in the cell proliferation, differentiation, migration, adhesion and apoptosis, which can affect the vascular remodeling in the humanbody. The main ligand of CaSR is extracellular Ca2+. CaSR has the p
Autor:
Aining Sun, Bingcheng Liu, Li Zhang, Xiaobao Xie, Chunting Zhao, Ming Jiang, Jie Jin, Jiuwei Cui, Zhang Mei, Xin Liu, Jianmin Luo, Yu Hu, Xiaoli Liu, Tong-hua Yang, Yanli Zhang, Jianxiang Wang, Li Liu, Jian-Hui Qiao, Jianyong Li, Hao Jiang, Li Meng, Jian Gu, Xi Zhang, Huanling Zhu, Yan Li, Guifang Ouyang, Wang-Gang Zhang
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(1)
Purpose: Flumatinib has been shown to be a more potent inhibitor of BCR-ABL1 tyrosine kinase than imatinib. We evaluated the efficacy and safety of flumatinib versus imatinib, for first-line treatment of chronic phase Philadelphia chromosome–positi
Autor:
Xin Wang, Lei Chen, Lin Cheng, Ying-Jian Gu, Mei-Jia Zhu, Lin Shi, Bing-Yang Liu, Ming-Yuan Zhou, Yun Wang
Publikováno v:
Cell Stress Chaperones
Lung toxicity is the main cause of the death from methamphetamine (MA) abuse, but its mechanism has remained unclear. The purpose of our study was to investigate if MA can induce epithelial-to-mesenchymal transition (EMT) and if RUNX3 is involved in
Autor:
Lin Shi, Lei Chen, Lin Cheng, Yun Wang, Ashok Kumar, Ming Liu, Xin Wang, Yuan-Ling Zhao, Lian Liu, Ying-Jian Gu, Ming-Yuan Zhou, Mei-Jia Zhu
Publikováno v:
Cell Proliferation
Objectives SIRT1 is an antioxidative factor, but its mechanism in methamphetamine (MA)‐induced lung injury remains unclear. The purpose of this study is to determine whether MA can disrupt the integrity of alveolar epithelial barrier, whether SIRT1
Publikováno v:
Cancers, Vol 12, Iss 3, p 594 (2020)
Cancers
Volume 12
Issue 3
Cancers
Volume 12
Issue 3
Background: Leukocyte telomere length (LTL) has been associated with the risks of several cancers in observational studies. Mendelian randomization (MR) studies, using genetic variants as instrumental variables, have also shown associations of geneti
Publikováno v:
Journal of Cellular and Molecular Medicine
Hepatocellular carcinoma (HCC) is the sixth most common malignant tumour, which has posed a heavy health and financial burden worldwide. Due to limited symptoms at the early stage and the limitation in current biomarkers, HCC patients are usually dia
Publikováno v:
The Journal of Clinical Pharmacology. 59:45-54
We performed a systematic review and meta-analysis to fully investigate the rash and pruritus of programmed death-1 (PD-1) inhibitors in cancer patients. The relevant studies of the randomized controlled trials in cancer patients treated with PD-1 in